12 research outputs found
Cross-cutting principles for planetary health education
Since the 2015 launch of the Rockefeller Foundation Lancet Commission on planetary health,1 an enormous groundswell of interest in planetary health education has emerged across many disciplines, institutions, and geographical regions. Advancing these global efforts in planetary health education will equip the next generation of scholars to address crucial questions in this emerging field and support the development of a community of practice. To provide a foundation for the growing interest and efforts in this field, the Planetary Health Alliance has facilitated the first attempt to create a set of principles for planetary health education that intersect education at all levels, across all scales, and in all regions of the world—ie, a set of cross-cutting principles
Recommended from our members
Conserving Line Vautrin’s Talosel resin objects
This paper presents the research and conservation of two plastic mirror frames by the celebrated mid20th century French designer Line Vautrin, which were encountered by the authors at the same time in private practices in New York and London. Vautrin’s prolific oeuvre in early 20th century semi-synthetic plastic is largely owned by private collectors; research showed that her favourite material ‘Talosel’ was patented by her and was in fact cellulose acetate (CA) sheet manipulated in various ways invented by Vautrin. The large volume of Vautrin’s work in Talosel resin is threatened today by the material’s inherently unstable aging characteristics and the lack of art historical reference to Vautrin. This case study discusses in detail the materials used by Vautrin, their inevitable degradation and the approach used to conserve one heavily deteriorated mirror so it could be hung on a wall again, despite knowing that it will only have a relatively short lifespan
Recommended from our members
Plastics in Peril: Focus on conservation of polymeric materials in cultural heritage
‘Plastics in Peril’ was originally planned by University of Cambridge Museums as an in-person conference to be held in March 2020 in Cambridge, UK. The global pandemic threw all plans out of the window and we found ourselves stuck at home in lockdown. The future of the meeting was very uncertain when the Leibniz Association of Research Museums in Germany contacted the Cambridge organisers to discuss their own plans for a conference on plastics conservation. In short, we decided to work together to host an online conference blending contributions from both meetings. This volume contains the 13 papers selected for the original in-person Cambridge conference, and they reflect many of the themes that came out in the wider joint meeting
Approaches and concepts of modelling denitrification: increased process understanding using observational data can reduce uncertainties
Cationic rhodium mono-phosphine fragments partnered with carborane monoanions [closo-CB11H6X6]– (X = H, Br). Synthesis, structures and reactivity with alkenes
Accounting for Carbon Stocks in Soils and Measuring GHGs Emission Fluxes from Soils: Do We Have the Necessary Standards?
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia.
We conducted a genome-wide association study of 299,983 tagging SNPs for chronic lymphocytic leukemia (CLL) and performed validation in two additional series totaling 1,529 cases and 3,115 controls. We identified six previously unreported CLL risk loci at 2q13 (rs17483466; P = 2.36 x 10(-10)), 2q37.1 (rs13397985, SP140; P = 5.40 x 10(-10)), 6p25.3 (rs872071, IRF4; P = 1.91 x 10(-20)), 11q24.1 (rs735665; P = 3.78 x 10(-12)), 15q23 (rs7176508; P = 4.54 x 10(-12)) and 19q13.32 (rs11083846, PRKD2; P = 3.96 x 10(-9)). These data provide the first evidence for the existence of common, low-penetrance susceptibility to a hematological malignancy and new insights into disease causation in CLL
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia
Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)
This chapter about antithrombotic therapy in neonates and children is part of the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs, and Grade 2 suggests that individual patient values may lead to different choices (for a full understanding of the grading, see Guyatt et al in this supplement, pages 123S-131S). In this chapter, many recommendations are based on extrapolation of adult data, and the reader is referred to the appropriate chapters relating to guidelines for adult populations. Within this chapter, the majority of recommendations are separate for neonates and children, reflecting the significant differences in epidemiology of thrombosis and safety and efficacy of therapy in these two populations. Among the key recommendations in this chapter are the following: In children with first episode of venous thromboembolism (VTE), we recommend anticoagulant therapy with either unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) [Grade 1B]. Dosing of IV UFH should prolong the activated partial thromboplastin time (aPTT) to a range that corresponds to an anti-factor Xa assay (anti-FXa) level of 0.35 to 0.7 U/mL, whereas LMWH should achieve an anti-FXa level of 0.5 to 1.0 U/mL 4 h after an injection for twice-daily dosing. In neonates with first VTE, we suggest either anticoagulation or supportive care with radiologic monitoring and subsequent anticoagulation if extension of the thrombosis occurs during supportive care (Grade 2C). We recommend against the use of routine systemic thromboprophylaxis for children with central venous lines (Grade 1B). For children with cerebral sinovenous thrombosis (CSVT) without significant intracranial hemorrhage (ICH), we recommend anticoagulation initially with UFH, or LMWH and subsequently with LMWH or vitamin K antagonists (VKAs) for a minimum of 3 months (Grade 1B). For children with non-sickle-cell disease-related acute arterial ischemic stroke (AIS), we recommend UFH or LMWH or aspirin (1 to 5 mg/kg/d) as initial therapy until dissection and embolic causes have been excluded (Grade 1B). For neonates with a first AIS, in the absence of a documented ongoing cardioembolic source, we recommend against anticoagulation or aspirin therapy (Grade 1B)